Payment overview · 2025
General Payments
$1,712.64
105 reported records · 18 companies
Healthcare provider profile · identity verified
Phillip D Compton, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GULFPORT, MS · NPI 1578591186
Verified facts
What the public records show
CMS Open Payments records show Phillip D Compton, M.D. received $1,712.64 in general payments during 2025 across 105 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Rexulti, Rybelsus, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 306 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 306 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Rexulti by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $373.92 | 21.8% | 18 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $196.08 | 11.4% | 18 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $171.72 | 10.0% | 10 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $158.99 | 9.3% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $153.59 | 9.0% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $151.21 | 8.8% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $143.25 | 8.4% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $79.85 | 4.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.95 | 3.7% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $53.96 | 3.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.11 | 2.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.03 | 1.9% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.68 | 1.3% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.90 | 1.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.07 | 1.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.40 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.95 | 0.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.98 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,626.50 | 101 |
| Education | $86.14 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $254.27 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $225.68 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $166.18 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $163.27 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $158.99 | 10 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $153.59 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $140.80 | 13 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $134.36 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $105.48 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $79.85 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $67.48 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $62.95 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $55.28 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.00 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $37.77 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $37.77 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.11 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.03 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.68 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.85 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.95 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 12 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 67 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 306 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 97 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 184 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 62 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 12 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 156 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
113 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
306 | 50 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
156 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
306 | 50 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
97 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
184 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
91 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
67 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2265 | 381 |
| Amlodipine Besylate | Amlodipine Besylate | 1446 | 281 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1293 | 188 |
| Gabapentin | Gabapentin | 1189 | 190 |
| Furosemide | Furosemide | 1112 | 189 |
| Pantoprazole Sodium | Pantoprazole Sodium | 939 | 188 |
| Trazodone Hcl | Trazodone Hcl | 854 | 138 |
| Potassium Chloride | Potassium Chloride | 852 | 156 |
| Eliquis | Apixaban | 850 | 93 |
| Losartan Potassium | Losartan Potassium | 766 | 163 |
| Omeprazole | Omeprazole | 691 | 152 |
| Sertraline Hcl | Sertraline Hcl | 630 | 131 |
| Metoprolol Tartrate | Metoprolol Tartrate | 618 | 126 |
| Tamsulosin Hcl | Tamsulosin Hcl | 617 | 108 |
| Lisinopril | Lisinopril | 566 | 110 |
| Metformin Hcl | Metformin Hcl | 559 | 106 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 535 | 113 |
| Clopidogrel | Clopidogrel Bisulfate | 501 | 87 |
| Buspirone Hcl | Buspirone Hcl | 493 | 62 |
| Escitalopram Oxalate | Escitalopram Oxalate | 491 | 81 |
| Quetiapine Fumarate | Quetiapine Fumarate | 486 | 69 |
| Famotidine | Famotidine | 466 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 447 | 116 |
| Meloxicam | Meloxicam | 424 | 87 |
| Carvedilol | Carvedilol | 423 | 81 |
| Duloxetine Hcl | Duloxetine Hcl | 397 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 388 | 88 |
| Levetiracetam | Levetiracetam | 380 | 42 |
| Donepezil Hcl | Donepezil Hcl | 361 | 57 |
| Memantine Hcl | Memantine Hcl | 354 | 51 |
| Allopurinol | Allopurinol | 346 | 53 |
| Hydralazine Hcl | Hydralazine Hcl | 336 | 64 |
| Baclofen | Baclofen | 327 | 58 |
| Jardiance | Empagliflozin | 306 | 50 |
| Citalopram Hbr | Citalopram Hydrobromide | 301 | 49 |
| Xarelto | Rivaroxaban | 297 | 35 |
| Divalproex Sodium | Divalproex Sodium | 285 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 279 | 77 |
| Montelukast Sodium | Montelukast Sodium | 263 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 255 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 253 | 86 |
| Glimepiride | Glimepiride | 249 | 55 |
| Midodrine Hcl | Midodrine Hcl | 248 | 43 |
| Ondansetron Hcl | Ondansetron Hcl | 238 | 72 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 221 | 47 |
| Mirtazapine | Mirtazapine | 214 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 212 | 73 |
| Alendronate Sodium | Alendronate Sodium | 194 | 45 |
| Oxybutynin Chloride | Oxybutynin Chloride | 193 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 191 | 34 |
| Methenamine Hippurate | Methenamine Hippurate | 188 | 24 |
| Olanzapine | Olanzapine | 184 | 26 |
| Ozempic | Semaglutide | 184 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 178 | 126 |
| Risperidone | Risperidone | 177 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 173 | 26 |
| Spironolactone | Spironolactone | 170 | 41 |
| Metformin Hcl Er | Metformin Hcl | 164 | 41 |
| Levofloxacin | Levofloxacin | 161 | 111 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 157 | 32 |
| Finasteride | Finasteride | 156 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 156 | 33 |
| Amiodarone Hcl | Amiodarone Hcl | 155 | 34 |
| Januvia | Sitagliptin Phosphate | 153 | 27 |
| Novolog | Insulin Aspart | 153 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 152 | 21 |
| Prednisone | Prednisone | 146 | 69 |
| Simvastatin | Simvastatin | 144 | 35 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 143 | 33 |
| Entresto | Sacubitril/Valsartan | 138 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 136 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 136 | 35 |
| Tramadol Hcl | Tramadol Hcl | 133 | 38 |
| Sucralfate | Sucralfate | 132 | 21 |
| Ezetimibe | Ezetimibe | 130 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 127 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 123 | 32 |
| Rivastigmine | Rivastigmine | 121 | 16 |
| Topiramate | Topiramate | 121 | 14 |
| Ibuprofen | Ibuprofen | 117 | 40 |
| Nifedipine Er | Nifedipine | 117 | 24 |
| Linzess | Linaclotide | 113 | 27 |
| Fluconazole | Fluconazole | 112 | 70 |
| Glipizide | Glipizide | 112 | 20 |
| Myrbetriq | Mirabegron | 110 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 110 | 71 |
| Paroxetine Hcl | Paroxetine Hcl | 110 | 23 |
| Latanoprost | Latanoprost | 109 | 22 |
| Nystatin | Nystatin | 109 | 41 |
| Lactulose | Lactulose | 108 | 37 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 106 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 106 | 20 |
| Bupropion Xl | Bupropion Hcl | 103 | 21 |
| Clonidine Hcl | Clonidine Hcl | 102 | 25 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 100 | 55 |
| Novolog Flexpen | Insulin Aspart | 100 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 19 |
| Mounjaro | Tirzepatide | 97 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 96 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 96 | 26 |
| Sodium Chloride | 0.9 % Sodium Chloride | 95 | 49 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 91 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 23 |
| Lubiprostone | Lubiprostone | 88 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 87 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 87 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 87 | 33 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 85 | 33 |
| Atenolol | Atenolol | 84 | 20 |
| Pregabalin | Pregabalin | 84 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 83 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 83 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 83 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 81 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 80 | 11 |
| Lamotrigine | Lamotrigine | 80 | 12 |
| Bupropion Hcl | Bupropion Hcl | 79 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 78 | 47 |
| Amitriptyline Hcl | Amitriptyline Hcl | 77 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 75 | 21 |
| Hydrocortisone | Hydrocortisone | 74 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 73 | 19 |
| Amoxicillin | Amoxicillin | 72 | 60 |
| Clonazepam | Clonazepam | 72 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 71 | 51 |
| Digoxin | Digoxin | 71 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 71 | suppressed |
| Ondansetron Odt | Ondansetron | 70 | 28 |
| Breo Ellipta | Fluticasone/Vilanterol | 69 | 13 |
| Gemtesa | Vibegron | 67 | 14 |
| Lidocaine Hcl | Lidocaine Hcl | 67 | 45 |
| Bupropion Hcl Sr | Bupropion Hcl | 66 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 64 | 14 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 64 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 63 | 50 |
| Benztropine Mesylate | Benztropine Mesylate | 62 | suppressed |
| Brilinta | Ticagrelor | 62 | suppressed |
| Rexulti | Brexpiprazole | 62 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 61 | 46 |
| Naproxen | Naproxen | 61 | 21 |
| Olanzapine Odt | Olanzapine | 60 | suppressed |
| Aripiprazole | Aripiprazole | 59 | suppressed |
| Alprazolam | Alprazolam | 58 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 58 | 46 |
| Celecoxib | Celecoxib | 57 | 15 |
| Primidone | Primidone | 57 | 12 |
| Lidocaine | Lidocaine | 56 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 16 |
| Megestrol Acetate | Megestrol Acetate | 55 | 27 |
| Benazepril Hcl | Benazepril Hcl | 54 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 54 | 12 |
| Acetic Acid | Acetic Acid | 53 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 53 | 37 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 52 | 14 |
| Metolazone | Metolazone | 52 | suppressed |
| Azithromycin | Azithromycin | 51 | 49 |
| Ertapenem | Ertapenem Sodium | 50 | 28 |
| Estradiol | Estradiol | 50 | 14 |
| Nuplazid | Pimavanserin Tartrate | 50 | suppressed |
| Calcitriol | Calcitriol | 49 | suppressed |
| Lansoprazole | Lansoprazole | 49 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 48 | 11 |
| Methocarbamol | Methocarbamol | 47 | 17 |
| Tradjenta | Linagliptin | 47 | suppressed |
| Clonidine | Clonidine | 46 | suppressed |
| Methylprednisolone | Methylprednisolone | 45 | 33 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 44 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 44 | 11 |
| Meclizine Hcl | Meclizine Hcl | 44 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 44 | 12 |
| Diltiazem 24hr Er | Diltiazem Hcl | 43 | suppressed |
| Ketoconazole | Ketoconazole | 43 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 43 | 11 |
| Rybelsus | Semaglutide | 42 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 42 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 41 | suppressed |
| Valsartan | Valsartan | 41 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 40 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 40 | 30 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | suppressed |
| Verapamil Er | Verapamil Hcl | 40 | suppressed |
| Xifaxan | Rifaximin | 40 | suppressed |
| Ramipril | Ramipril | 39 | 11 |
| Farxiga | Dapagliflozin Propanediol | 38 | 11 |
| Lorazepam | Lorazepam | 38 | 13 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Haloperidol | Haloperidol | 37 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 37 | 13 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 36 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 36 | suppressed |
| Glipizide Er | Glipizide | 36 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 36 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 36 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Levemir | Insulin Detemir | 35 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 15 |
| Insulin Aspart | Insulin Aspart | 34 | 14 |
| Nitroglycerin | Nitroglycerin | 34 | 17 |
| Acarbose | Acarbose | 33 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 33 | 13 |
| Insulin Lispro | Insulin Lispro | 33 | 11 |
| Lovastatin | Lovastatin | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 32 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 31 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 31 | suppressed |
| Humalog | Insulin Lispro | 31 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 31 | suppressed |
| Timolol Maleate | Timolol Maleate | 31 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 31 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 30 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 30 | suppressed |
| Levemir Flexpen | Insulin Detemir | 30 | 15 |
| Torsemide | Torsemide | 30 | suppressed |
| Methimazole | Methimazole | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | 13 |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 28 | suppressed |
| Minoxidil | Minoxidil | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 26 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 25 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Metronidazole | Metronidazole | 25 | 21 |
| Ongentys | Opicapone | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 25 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 25 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Scopolamine | Scopolamine | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 22 | 12 |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 22 | 16 |
| Spiriva Handihaler | Tiotropium Bromide | 22 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 21 | 11 |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Glucagon Emergency Kit | Glucagon | 20 | 11 |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Hydroxyurea | Hydroxyurea | 19 | suppressed |
| Ingrezza | Valbenazine Tosylate | 19 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 19 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 18 | suppressed |
| Cefdinir | Cefdinir | 18 | 17 |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Erythromycin | Erythromycin Base | 18 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Meropenem | Meropenem | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Victoza 3-Pak | Liraglutide | 18 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 17 | suppressed |
| Linezolid | Linezolid | 17 | 15 |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 16 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Restasis | Cyclosporine | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 15 | suppressed |
| Indomethacin | Indomethacin | 15 | suppressed |
| Meropenem-0.9% Nacl | Meropenem-0.9% Sodium Chloride | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 14 | suppressed |
| Enulose | Lactulose | 14 | 13 |
| Felodipine Er | Felodipine | 14 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 14 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Renvela | Sevelamer Carbonate | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | 12 |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Briviact | Brivaracetam | 11 | suppressed |
| Entacapone | Entacapone | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Jublia | Efinaconazole | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 11 | suppressed |
| Zolmitriptan Odt | Zolmitriptan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,712.64 · 105 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, Cologuard Collection Kit, EVENITY, FARXIGA, FREESTYLE LIBRE, GEMTESA, GVOKE HYPOPEN, JARDIANCE, Kerendia, Korlym, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Wegovy, YUPELRI, ZEPBOUND | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error